Manidipino Cinfa

Manidipine, the active ingredient in Manidipino Cinfa, is a calcium channel blocker presented as a tablet for oral use. It is employed to lower elevated blood pressure in adult patients with hypertension. By selectively inhibiting L‑type calcium channels in vascular smooth muscle, it promotes vasodilation and reduces peripheral resistance, helping to achieve target blood‑pressure goals.

GNH USA supplies Manidipino Cinfa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manidipine is used to manage hypertension, a condition characterized by chronically elevated arterial pressure.

- Essential hypertension: reduces both systolic and diastolic blood pressure to target levels. - Isolated systolic hypertension: helps control high systolic readings especially in older adults. - Secondary hypertension (renovascular): may be used as part of combination therapy to achieve blood‑pressure control.

Manidipine may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of the ankles or lower legs. - Dizziness or light‑headedness, especially after standing. - Nausea or abdominal discomfort. - Tachycardia: slight increase in heart rate.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Angioedema: swelling of the face, lips, tongue or throat. - Hepatic dysfunction: abnormal liver enzyme elevations. - Myocardial infarction or acute coronary syndrome. - Life‑threatening arrhythmias.

Before initiating therapy, clinicians should consider several safety aspects.

- Blood pressure monitoring: check regularly to ensure adequate control and avoid excessive drops. - Hepatic impairment: use with caution and adjust dose if liver function is compromised. - Elderly patients: start at the lowest effective dose and monitor for orthostatic effects. - Concomitant vasodilators: assess risk of additive hypotensive effects. - Severe aortic stenosis: contraindicated due to risk of reflex tachycardia. - Store at below 25°C: keep in the original pack, protect from moisture and direct sunlight.

Manidipine can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Other calcium‑channel blockers (e.g., amlodipine, verapamil): may cause additive hypotension. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase plasma concentrations. - Grapefruit juice: can elevate drug levels and precipitate adverse effects.

Moderate Interactions (Monitor Closely):\n- Diuretics: may enhance blood‑pressure lowering effect. - Beta‑blockers: combined use may require dose adjustments. - ACE inhibitors or ARBs: monitor renal function and potassium. - NSAIDs: may blunt antihypertensive response. - Antidiabetic agents: watch for changes in glucose control.